With a whopping 75,000 cases reported and constantly rising cases and death reports, the immediate need for vaccines is inevitable. Currently, there is no vaccine authorized for the infection. A vaccine is not expected for at least another year, suggesting even that being optimistic. Even if a vaccine produced there is no certainty of complete immunity against the infection. Below are two promising vaccine potentials:
Voltron Therapeutics: This US-based company, last month collaborated with Massachusetts General Hospital. A self-assembling vaccine (SAV) technology is adopted by the company to develop the vaccine. The animal trials are set to launch in late April. Above-adopted technology is different from traditional vaccines that use a weakened form of the virus to trigger immune reactions. Since the virus itself is not involved, this is termed safer.
Coroflu, Bharat Biotech: Bharat Biotech is set to collaborate with the University of Wisconsin- Madison and pharma company FluGen to develop a vaccine called Coorflu, to be administered intranasally. The teams will work together to incorporate parts of the genome of the COVID-19 virus into the structure and test the results. It is believed to be at least three to six months before the clinical trials can take place.
To know more about origin, virology of COVID-19, Click here
To know more about emerging themes in COVID-19, Click here
To know more about how WhiteCoats can help you in your professional advancement, visit www.whitecoats.com
Want to set up an online consultation for your practice, Click here